24-Weekly vs. 12-Weekly Triptorelin: Clinical Equivalence and Enhanced Adherence in Central Precocious Puberty
Highlights of the Comparative Analysis
The management of central precocious puberty (CPP) has seen a significant shift toward long-acting formulations to improve patient quality of life. The recent UK multicentre retrospective cohort study provides several critical insights for clinicians:
1. Clinical Equivalence: The 24-weekly administration of Decapeptyl SR (22.5 mg) provides suppression of the hypothalamic-pituitary-gonadal (HPG) axis equivalent to the traditional 12-weekly (11.25 mg) regimen.
2. Stable Anthropometrics: No significant differences were observed in height velocity, body mass index (BMI) SDS, or Tanner staging progression between the two groups.
3. Patient Preference: 100% of patients and families who expressed a preference favored the 24-weekly schedule, citing reduced injection frequency and less disruption to daily life.
4. Safety and Tolerability: Both regimens were well-tolerated, with no new safety signals identified for the longer-acting preparation.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.